Aromatase inhibitor letrozole guards against breast cancer relapse for up to 8 years
Sunday, September 25, 2011 - 12:30
in Health & Medicine
Stockholm, Sweden: Results from the longest-running trial comparing tamoxifen with the aromatase inhibitor letrozole show unequivocally that letrozole has withstood the test of time and continues to prevent breast cancer recurrences and reduce the risk of death in post-menopausal women with hormone receptor-positive early breast cancer.